Does Medicare Cover Foundayo (Orforglipron) in 2026?
Short answer: yes, at $50/month for eligible Medicare Part D enrollees, live since July 1, 2026, under the CMS Medicare GLP-1 Bridge program (which also covers Wegovy and the Zepbound KwikPen). That is unusual for a weight-loss GLP-1 (federal law normally excludes weight-loss-only drugs from Part D), and it makes the Bridge the most accessible Medicare GLP-1 path - no documented cardiovascular disease required. Below: how the Bridge works, plus the LillyDirect cash-pay alternative at $149/month if your plan has not added Foundayo yet.
Foundayo on Medicare: who pays what
| Patient situation | Monthly cost |
|---|---|
| Medicare Part D, plan includes Foundayo on formulary (since July 1, 2026) | $50 |
| Medicare Part D + Extra Help / LIS | $0 - $11 |
| Medicare Advantage (plan includes Foundayo) | $50 (typically) |
| Medicare beneficiary, plan has not added Foundayo (current state for most plans) | $149 |
| Cash retail (full WAC) | $1,099 |
The $50/month tier is the CMS Medicare GLP-1 Bridge, live since July 1, 2026. Whether YOUR plan participates and has Foundayo on formulary at the Bridge tier varies plan by plan as of July 2026 - confirm with your specific Part D plan administrator.
The Medicare Modernization Act and why Foundayo's Medicare tier is unusual
Section 1860D-2(e)(2)(A) of the Medicare Modernization Act of 2003 excludes “drugs when used for anorexia, weight loss, or weight gain” from Medicare Part D coverage. That law has been in continuous effect since 2006 (when Part D launched) and is the reason traditional Medicare has historically not covered Wegovy or Saxenda for weight loss alone.
Two known workarounds existed before Foundayo's approval: (1) Wegovy received a 2024 cardiovascular-disease (CVD) label expansion based on the SELECT trial, which allowed Part D coverage for ASCVD patients only - not for weight loss alone; (2) Mounjaro and Ozempic have Medicare coverage for their FDA-approved type-2 diabetes indication, but explicitly not for off-label weight-loss use.
Foundayo's announced $50/month Medicare tier appears to be a third workaround: a direct manufacturer-pricing mechanism that makes Foundayo accessible to Medicare beneficiaries at a flat sub-formulary price, independent of any non-weight-loss indication. The implementation details are still emerging, but if executed as announced this would be a meaningful expansion of Medicare GLP-1 access.
What to do before July 1, 2026
If you are a Medicare beneficiary considering Foundayo:
- Get a prescription now. Foundayo is FDA-approved and available via LillyDirect, retail (CVS, Walgreens), and Ro since April 2026. The prescription is the same whether you intend to pay via Medicare or via cash-pay.
- Pay cash via LillyDirect for the May-June bridge. $149/month for the lowest dose at lilly.com/lillydirect/medicines/foundayo. Stay within the 45-day refill window to keep that tier.
- After July 1, 2026, check your Part D plan's formulary. Look for “Foundayo” or “orforglipron” on the preferred drug list. If listed, your plan should honor the $50/month Lilly-tier pricing for eligible enrollees.
- If your plan has not added Foundayo, file a formulary exception request. Your prescriber submits documentation; the plan has 72 hours for a standard decision, 24 hours for expedited.
Cash-pay LillyDirect as the Medicare backup
Whether your Part D plan adds Foundayo or not, LillyDirect at $149/month for the lowest dose (up to $299/month for higher doses within the 45-day refill window) is available to Medicare beneficiaries directly. Medicare status does not exclude you from LillyDirect cash-pay - the federal anti-kickback statute applies to manufacturer copay-assistance programs that reduce a Medicare-set copay, not to direct manufacturer cash-pay programs that operate outside the Part D framework.
Practically: even after July 1, 2026, if your plan has not added Foundayo or has placed it on a high tier, LillyDirect cash-pay at $149/month may still beat your Part D copay. Run the math both ways.
Visit LillyDirect →How this compares to Wegovy Medicare coverage
Wegovy gained limited Medicare Part D coverage in March 2024 after the FDA expanded its label to include cardiovascular-disease prevention in ASCVD patients (based on the SELECT trial). To qualify for Medicare-covered Wegovy, a patient needs documented atherosclerotic cardiovascular disease on their chart - prior MI, prior stroke, prior peripheral arterial disease with vascular workup, or prior coronary/peripheral revascularization. Without ASCVD, Medicare denies Wegovy.
Foundayo's announced $50/month Medicare-eligible tier does not appear to require a non-weight-loss indication. This makes Foundayo the more accessible Medicare GLP-1 option for the large population of Medicare beneficiaries who have obesity but do not yet have qualifying cardiovascular disease.
For the full Wegovy Medicare framework see Does Medicare Cover Wegovy.
Frequently asked questions
Does Medicare cover Foundayo?
Yes, via a specific CMS program: the Medicare GLP-1 Bridge, live since July 1, 2026, gives eligible Medicare Part D enrollees a flat $50/month copay for Foundayo. This is unusual for a weight-loss GLP-1 because the Medicare Modernization Act of 2003 statutorily excludes drugs used solely for weight loss from Part D. The Bridge is a CMS demonstration structured to reach Medicare-eligible patients at the $50 tier despite that exclusion - and it is not Foundayo-exclusive; Wegovy and Zepbound KwikPen are covered under the same program.
How does the $50/month Medicare price actually work mechanically?
The Medicare GLP-1 Bridge is a CMS demonstration that participating Part D plans opt into. When a plan participates and adds Foundayo to its formulary at the Bridge tier, eligible enrollees pay a flat $50 copay regardless of the drug's underlying negotiated price. Confirm with your specific Part D plan administrator - the cleanest signal is whether your plan portal shows Foundayo on formulary at the Bridge tier.
When did the $50/month Medicare tier go live?
July 1, 2026, on schedule, under the CMS Medicare GLP-1 Bridge. Before that date, Medicare beneficiaries could purchase Foundayo through LillyDirect cash-pay at $149/month for the lowest dose or up to $299/month for higher doses within the 45-day refill window - that cash-pay path remains available as a fallback for anyone whose plan has not added Foundayo at the Bridge tier.
Is Foundayo on my Part D plan's formulary?
Varies by plan. Part D plans run formulary updates on quarterly cycles, and Foundayo only received FDA approval April 1, 2026, so many plans took until Q3 2026 or later to add it. Check your specific plan's member portal or call Member Services to confirm current Foundayo coverage status and whether it is at the Bridge $50 tier.
Does Medicare Advantage cover Foundayo?
Coverage rules are generally the same - Medicare Advantage plans must cover at least everything traditional Medicare plus Part D covers, but they administer their own formularies and prior-authorization requirements. Some Medicare Advantage plans (especially those that consider obesity care a quality measure) may add Foundayo to formulary faster than traditional Medicare Part D plans. Check your specific Medicare Advantage plan's formulary on its member portal. If your plan covers Foundayo, the $50/month Medicare GLP-1 Bridge tier typically applies for eligible enrollees.
Can I use a Foundayo savings card with Medicare?
No - federal anti-kickback statute prohibits manufacturer copay-assistance programs from being used by patients with government insurance (Medicare, Medicaid, Tricare, VA). The Medicare GLP-1 Bridge is a separate CMS program (not a Lilly savings card) structured to reach Medicare beneficiary status by working through the Part D benefit itself rather than manufacturer copay assistance. The $50/month Bridge tier is the Medicare-specific path; there is no separate Foundayo Savings Card for Medicare.
What if Medicare denies Foundayo or it's not on my plan's formulary?
Two options. (1) Use LillyDirect self-pay at $149/month for the lowest dose. As of July 2026, this is the cheapest cash-pay path for Medicare beneficiaries whose Part D plan has not yet added Foundayo. Available at lilly.com/lillydirect/medicines/foundayo. (2) File a Part D formulary exception request through your plan, citing Foundayo's unique status as the only daily oral GLP-1 with no food or water restrictions, especially if other GLP-1s have failed for tolerability reasons. Exception decisions typically take 7-14 days for standard requests, 24 hours for expedited.
What if I have Medicare and qualify for Extra Help (LIS)?
Low-Income Subsidy (Extra Help) reduces Part D copays substantially - typically to $0-$11/month for covered drugs in 2026. If your Part D plan covers Foundayo and you qualify for full LIS, your out-of-pocket could be below the standard $50/month Lilly-tier price. LIS does not help if Foundayo is not yet on your plan's formulary - in that case the underlying coverage gap matters more than the subsidy, and you would need to use LillyDirect cash-pay or pursue a formulary exception.
How does Foundayo Medicare coverage compare to Wegovy Medicare coverage?
As of July 1, 2026, they run through the SAME program - the Medicare GLP-1 Bridge covers Foundayo, Wegovy (injection and oral), and Zepbound KwikPen at an identical flat $50/month copay, under a broader eligibility standard (BMI ≥35, or BMI ≥30 with a qualifying comorbidity, or BMI ≥27 with prediabetes or prior cardiovascular disease - no ASCVD documentation required). This supersedes Wegovy's narrower 2024 Medicare pathway, which required documented atherosclerotic cardiovascular disease (prior MI, stroke, or revascularization) and did not offer a flat copay. Foundayo is not more Medicare-accessible than Wegovy under current rules - both reach the same $50 tier through the Bridge. The genuine differentiator between the two drugs is the daily-pill-vs-weekly-injection format, not Medicare access.
Does Medicaid cover Foundayo?
Medicaid GLP-1 coverage is determined state-by-state and is not yet broadly established for Foundayo as of July 2026. Some states (California, New York, Massachusetts among others) have shown willingness to add newly-approved obesity drugs to Medicaid formularies on faster cycles; others (Texas, Florida) typically wait 6-12 months post-approval. Check your state Medicaid agency's preferred drug list (PDL). Federal Medicaid rules require coverage of FDA-approved indications when prescribed appropriately, but states have flexibility on prior-authorization criteria and step-therapy requirements.
Related guides
Track Foundayo (orforglipron) pricing and availability
Eli Lilly's daily oral pill Foundayo (orforglipron) was FDA-approved April 1, 2026 and starts at $149/mo via LillyDirect. We'll email you when pricing tiers change, insurance coverage expands, or new head-to-head data lands vs. Wegovy and Zepbound.